-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UuaJcHSENjNaQJq6HFHponPwsZHvmarKkhiX3yqBBtb/tV6KoR6551q2R7YPtUea u1wljaLwWJJvr0IidAm32g== 0001125282-05-005145.txt : 20051004 0001125282-05-005145.hdr.sgml : 20051004 20051004172828 ACCESSION NUMBER: 0001125282-05-005145 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050930 FILED AS OF DATE: 20051004 DATE AS OF CHANGE: 20051004 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INKINE PHARMACEUTICAL CO INC CENTRAL INDEX KEY: 0000929547 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133754005 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1787 SENTRY PARKWAY WEST STREET 2: BUILDING 18 SUITE 440 CITY: BLUE BELL STATE: PA ZIP: 19422 BUSINESS PHONE: 2152836850 MAIL ADDRESS: STREET 1: 1787 SENTRY PARKWAY WEST STREET 2: BUILDING 18 SUITE 440 CITY: BLUE BELL STATE: PA ZIP: 19422 FORMER COMPANY: FORMER CONFORMED NAME: PANAX PHARMACEUTICAL CO LTD DATE OF NAME CHANGE: 19940906 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROSE MARTIN CENTRAL INDEX KEY: 0001086883 STATE OF INCORPORATION: NY FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-25572 FILM NUMBER: 051122781 BUSINESS ADDRESS: BUSINESS PHONE: 6102609364 MAIL ADDRESS: STREET 1: INKINE PHARMACEUTICAL CO INC STREET 2: SENTRY PARK EAST 1720 WALTON ROAD CITY: BLUE BELL STATE: PA ZIP: 19422 4 1 form.xml X0202 4 2005-09-30 1 0000929547 INKINE PHARMACEUTICAL CO INC INKP 0001086883 ROSE MARTIN 1787 SENTRY PARKWAY WEST BUILDING 18 SUITE 440 BLUE BELL PA 19422 1 Exec VP for R&D Common Stock 2005-09-30 4 D 0 138100 D 0 D Common Stock 2005-09-30 4 D 0 20040 D 0 D Common Stock (right to buy) 1.50 2005-09-30 4 D 0 250000 D 2009-02-28 Common Stock 250000 0 D Common Stock (right to buy) 3.063 2005-09-30 4 D 0 20000 D 2010-01-13 Common Stock 20000 0 D Common Stock (right to buy) 7.656 2005-09-30 4 D 0 45000 D 2010-11-19 Common Stock 45000 0 D Common Stock (right to buy) 3.56 2005-09-30 4 D 0 35000 D 2011-05-15 Common Stock 35000 0 D Common Stock (right to buy) 0.83 2005-09-30 4 D 0 22500 D 2011-09-30 Common Stock 22500 0 D Common Stock (right to buy) 1.30 2005-09-30 4 D 0 45000 D 2012-02-27 Common Stock 45000 0 D Common Stock (right to buy) 1.05 2005-09-30 4 D 0 90000 D 2012-05-22 Common Stock 90000 0 D Common Stock (right to buy) 0.80 2005-09-30 4 D 0 35000 D 2012-08-04 Common Stock 35000 0 D Common Stock (right to buy) 2.82 2005-09-30 4 D 0 40000 D 2013-06-01 Common Stock 40000 0 D Common Stock (right to buy) 2.96 2005-09-30 4 D 0 50000 D 2015-03-27 Common Stock 50000 0 D Disposed of pursuant to merger agreement between Salix Pharmaceuticals, Ltd. ("Salix) and InKine Pharmaceutical Company, Inc. As a result of the merger, the reporting person received 0.1737 share of Salix common stock for each share of InKine common stock. Consists of fully vested restricted shares of common stock disposed of pursuant to merger agreement between Salix Pharmaceuticals, Ltd. ("Salix) and InKine Pharmaceutical Company, Inc. As a result of the merger, the reporting person received 0.1737 shares of Salix common stock for each share of InKine common stock. All of the options described above were converted in the merger into options to purchase Salix common stock based on an exchange ratio of 0.1737. These options, which are fully vested, now represent the right to purchase 109,865 shares of Salix common stock at a weighted average exercise price of $12.43 per share. Robert F. Apple, as attorney-in-fact for Martin Rose, M.D., J.D. 2005-10-04 -----END PRIVACY-ENHANCED MESSAGE-----